Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s LymphomaStephen M. Ansell, David J. Straus, Radhakrishnan Ramchandren et al.|New England Journal of Medicine|2022Cited by 342
Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) in the Phase III POLARIX StudyJonathan W. Friedberg, Jeff P. Sharman, Carrie A. Thompson et al.|Blood|2022Cited by 6
Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 StudyNancy L. Bartlett, Marco Picardi, David J. Straus et al.|Blood|2019Cited by 1